RESUMEN
Isotopic labeling studies of primary metabolism frequently utilize GC/MS to quantify (13)C in protein-hydrolyzed amino acids. During processing some amino acids are degraded, which reduces the size of the measurement set. The advent of high-resolution mass spectrometers provides a tool to assess molecular masses of peptides with great precision and accuracy and computationally infer information about labeling in amino acids. Amino acids that are isotopically labeled during metabolism result in labeled peptides that contain spatial and temporal information that is associated with the biosynthetic origin of the protein. The quantification of isotopic labeling in peptides can therefore provide an assessment of amino acid metabolism that is specific to subcellular, cellular, or temporal conditions. A high-resolution orbital trap was used to quantify isotope labeling in peptides that were obtained from unlabeled and isotopically labeled soybean embryos and Escherichia coli cultures. Standard deviations were determined by estimating the multinomial variance associated with each element of the m/z distribution. Using the estimated variance, quantification of the m/z distribution across multiple scans was achieved by a nonlinear fitting approach. Observed m/z distributions of uniformly labeled E. coli peptides indicated no significant differences between observed and simulated m/z distributions. Alternatively, amino acid m/z distributions obtained from GC/MS were convolved to simulate peptide m/z distributions but resulted in distinct profiles due to the production of protein prior to isotopic labeling. The results indicate that peptide mass isotopologue measurements faithfully represent mass distributions, are suitable for quantification of isotope-labeling-based studies, and provide additional information over existing methods.
Asunto(s)
Técnicas de Cultivo , Espectrometría de Masas/métodos , Fragmentos de Péptidos/metabolismo , Secuencia de Aminoácidos , Biomasa , Isótopos de Carbono , Escherichia coli/crecimiento & desarrollo , Escherichia coli/metabolismo , Proteínas de Escherichia coli/metabolismo , Cromatografía de Gases y Espectrometría de Masas , Marcaje Isotópico , Fragmentos de Péptidos/química , Proteínas de Plantas/metabolismo , Semillas/crecimiento & desarrollo , Semillas/metabolismo , Glycine max/crecimiento & desarrollo , Glycine max/metabolismoRESUMEN
Combination of the structure-based design and solid-phase parallel synthesis provided an integrated approach to rapidly develop the structure-activity relationship of benzopyran COX-2 inhibitors. Binding free energies predicted by free energy perturbation theory yielded good agreement with experimental results. New potent and selective lead compounds with improved metabolic properties were identified.
Asunto(s)
Benzopiranos/química , Inhibidores de la Ciclooxigenasa 2/química , Ciclooxigenasa 2/química , Microsomas/metabolismo , Animales , Benzopiranos/síntesis química , Benzopiranos/farmacología , Química Farmacéutica , Ciclooxigenasa 2/metabolismo , Inhibidores de la Ciclooxigenasa 2/síntesis química , Inhibidores de la Ciclooxigenasa 2/farmacología , Humanos , Unión Proteica , Ratas , Relación Estructura-Actividad , TermodinámicaRESUMEN
Human recombinant COX-1 and COX-2 was prepared in a purified form. The genes were cloned and expressed in insect cells, extracted by detergents, and purified by ion-exchange followed by size exclusion chromatography. Insect cells from 10 L fermentation yielded 2.3 mg of COX-1 with an overall yield of 75%, and 29 mg of COX-2 with an overall yield of 45%. Enzyme prepared in this manner was fully active and proved to be useful in biophysical studies including direct binding studies. The COX-2 provided material that was subsequently used in X-ray crystallography studies.
Asunto(s)
Cromatografía en Gel/métodos , Cromatografía por Intercambio Iónico/métodos , Ciclooxigenasa 1/aislamiento & purificación , Ciclooxigenasa 2/aislamiento & purificación , Proteínas Recombinantes/aislamiento & purificación , Animales , Clonación Molecular , Ciclooxigenasa 1/genética , Ciclooxigenasa 1/metabolismo , Ciclooxigenasa 2/genética , Ciclooxigenasa 2/metabolismo , Electroforesis en Gel de Poliacrilamida , Humanos , Insectos/citología , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismoRESUMEN
Cyclooxygenases (COX), or Prostaglandin H Synthases (PGHS), are the target enzymes for nonsteroidal anti-inflammatory drugs (NSAIDS). The identification of two isoforms of COX nearly 20 years ago stimulated a flurry of research activity to identify novel, selective inhibitors that could provide potential benefit over existing nonselective NSAIDS. An important contribution to this discovery effort was the development of various in vitro and in vivo assays to support rapid screening of chemical libraries, characterization of inhibitory mechanism, and determination of potency and efficacy to guide follow-up medicinal chemistry efforts. Several assay methods for the in vitro evaluation of COX activity and mechanism of inhibition by test compounds will be reviewed. Each of these methods has inherent advantages and disadvantages with regard to application and the mechanistic detail provided.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Inhibidores de la Ciclooxigenasa/farmacología , Pruebas de Enzimas/métodos , Prostaglandina-Endoperóxido Sintasas/metabolismo , Animales , Dinoprostona/metabolismo , Electroquímica/métodos , Electrodos , Ensayo de Inmunoadsorción Enzimática/métodos , Cinética , Oxígeno/metabolismo , Peroxidasa/metabolismoRESUMEN
Inflammation-induced microsomal prostaglandin E synthase-1 (mPGES-1) is the terminal enzyme that synthesizes prostaglandin E(2) (PGE(2)) downstream of cyclooxygenase-2 (COX-2). The efficacy of nonsteroidal anti-inflammatory drugs and COX-2 inhibitors in the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and inflammatory pain, largely attributed to the inhibition of PGE(2) synthesis, provides a rationale for exploring mPGES-1 inhibition as a potential novel therapy for these diseases. Toward this aim, we identified PF-9184 as a novel mPGES-1 inhibitor. PF-9184 potently inhibited recombinant human (rh) mPGES-1 (IC(50)=16.5+/-3.8nM), and had no effect against rhCOX-1 and rhCOX-2 (>6500-fold selectivity). In inflammation and clinically relevant biological systems, mPGES-1 expression, like COX-2 expression was induced in cell context- and time-dependent manner, consistent with the kinetics of PGE(2) synthesis. In rationally designed cell systems ideal for determining direct effects of the inhibitors on mPGES-1 function, but not its expression, PF-9184 inhibited PGE(2) synthesis (IC(50) in the range of 0.5-5 microM in serum-free cell and human whole blood cultures, respectively) while sparing the synthesis of 6-keto-PGF(1alpha) (PGF(1alpha)) and PGF(2alpha). In contrast, as expected, the selective COX-2 inhibitor, SC-236, inhibited PGE(2), PGF(1alpha) and PGF(2alpha) synthesis. This profile of mPGES-1 inhibition, distinct from COX-2 inhibition in cells, validates mPGES-1 as an attractive target for therapeutic intervention.
Asunto(s)
Óxidos S-Cíclicos/antagonistas & inhibidores , Inhibidores de la Ciclooxigenasa 2/farmacología , Oxidorreductasas Intramoleculares/antagonistas & inhibidores , Tiazinas/antagonistas & inhibidores , Animales , Artritis Reumatoide/metabolismo , Carragenina/farmacología , Células Cultivadas , Ciclooxigenasa 2/biosíntesis , Ciclooxigenasa 2/efectos de los fármacos , Ciclooxigenasa 2/metabolismo , Fibroblastos/efectos de los fármacos , Fibroblastos/enzimología , Expresión Génica/efectos de los fármacos , Humanos , Immunoblotting , Interleucina-1beta/farmacología , Oxidorreductasas Intramoleculares/biosíntesis , Oxidorreductasas Intramoleculares/metabolismo , Microsomas/efectos de los fármacos , Microsomas/enzimología , Prostaglandina-E Sintasas , Ratas , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Inducible, microsomal prostaglandin E synthase 1 (mPGES-1), the terminal enzyme in the prostaglandin (PG) biosynthetic pathway, constitutes a promising therapeutic target for the development of new anti-inflammatory drugs. To elucidate structure-function relationships and to enable structure-based design, an mPGES-1 homology model was developed using the three-dimensional structure of the closest homologue of the MAPEG family (Membrane Associated Proteins in Eicosanoid and Glutathione metabolism), mGST-1. The ensuing model of mPGES-1 is a homo-trimer, with each monomer consisting of four membrane-spanning segments. Extensive structure refinement revealed an inter-monomer salt bridge (K26-E77) as well as inter-helical interactions within each monomer, including polar hydrogen bonds (e.g. T78-R110-T129) and hydrophobic pi-stacking (F82-F103-F106), all contributing to the overall stability of the homo-trimer of mPGES-1. Catalytic co-factor glutathione (GSH) was docked into the mPGES-1 model by flexible optimization of both the ligand and the protein conformations, starting from the initial location ascertained from the mGST-1 structure. Possible binding site for the substrate, prostaglandin H(2) (PGH(2)), was identified by systematically probing the refined molecular structure of mPGES-1. A binding model was generated by induced fit docking of PGH(2) in the presence of GSH. The homology model prescribes three potential inhibitor binding sites per mPGES-1 trimer. This was further confirmed experimentally by equilibrium dialysis study which generated a binding stoichiometric ratio of approximately three inhibitor molecules to three mPGES-1 monomers. The structural model that we have derived could serve as a useful tool for structure-guided design of inhibitors for this emergently important therapeutic target.
Asunto(s)
Inhibidores Enzimáticos/química , Oxidorreductasas Intramoleculares/química , Microsomas/enzimología , Secuencia de Aminoácidos , Biopolímeros , Inhibidores Enzimáticos/farmacología , Humanos , Oxidorreductasas Intramoleculares/antagonistas & inhibidores , Oxidorreductasas Intramoleculares/metabolismo , Modelos Moleculares , Datos de Secuencia Molecular , Prostaglandina-E Sintasas , Conformación Proteica , Homología de Secuencia de AminoácidoRESUMEN
Leukotrienes are important mediators in a number of inflammatory diseases and therefore are a target of several therapeutic approaches. The first committed step in the synthesis of leukotrienes is the conversion of arachidonic acid to leukotriene A(4) (LTA(4)) in two successive reactions catalyzed by 5-lipoxygenase (5-LOX). Assays to measure 5-LOX activity typically have been low throughput and time consuming. In this article, we describe a fluorescence assay that is amenable to high-throughput screening in a 384-well microplate format. The fluorescent signal is measured during oxidation of 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) by human 5-LOX. The assay has been found to reliably identify small molecule inhibitors of human 5-LOX. The IC(50) values of several 5-LOX inhibitors in this new assay are comparable to those determined in a standard spectrophotometric assay that measures the formation of the 5(S)-hydroperoxyeicosatetraenoic acid (5-HpETE) product. In addition, we demonstrate the use of the assay in a high-throughput screen of the Pfizer compound collection to identify inhibitors of 5-LOX.
Asunto(s)
Araquidonato 5-Lipooxigenasa/aislamiento & purificación , Inhibidores de la Lipooxigenasa/análisis , Inhibidores de la Lipooxigenasa/química , Espectrofotometría Ultravioleta/métodos , Compuestos Cromogénicos/química , Clonación Molecular/métodos , Evaluación Preclínica de Medicamentos/métodos , Fluoresceínas/química , Fluorescencia , Colorantes Fluorescentes/análisis , Colorantes Fluorescentes/química , Humanos , Indicadores y Reactivos , Concentración 50 Inhibidora , Leucotrieno A4/química , Leucotrienos/química , Sensibilidad y Especificidad , Especificidad por SustratoRESUMEN
The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing prostaglandin formation from COX-1. Celecoxib and rofecoxib were among the molecules developed from these efforts. We report here the pharmacological properties of a third selective COX-2 inhibitor, valdecoxib, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied. Recombinant human COX-1 and COX-2 were used to screen for new highly potent and in vitro selective COX-2 inhibitors and compare kinetic mechanisms of binding and enzyme inhibition with other COX inhibitors. Valdecoxib potently inhibits recombinant COX-2, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib. Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib). The overall saturation binding affinity for COX-2 of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min). Valdecoxib inhibits COX-1 in a competitive fashion only at very high concentrations (IC(50) = 150 microM). Collectively, these data provide a mechanistic basis for the potency and in vitro selectivity of valdecoxib for COX-2. Valdecoxib showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM). We also determined whether this in vitro potency and selectivity translated to significant potency in vivo. In rats, valdecoxib demonstrated marked potency in acute and chronic models of inflammation (air pouch ED(50) = 0.06 mg/kg; paw edema ED(50) = 5.9 mg/kg; adjuvant arthritis ED(50) = 0.03 mg/kg). In these same animals, COX-1 was spared at doses greater than 200 mg/kg. These data provide a basis for the observed potent anti-inflammatory activity of valdecoxib in humans.
Asunto(s)
Inhibidores de la Ciclooxigenasa/farmacología , Isoxazoles/farmacología , Prostaglandina-Endoperóxido Sintasas/efectos de los fármacos , Sulfonamidas/farmacología , Animales , Antiinflamatorios no Esteroideos/farmacología , Artritis Experimental/tratamiento farmacológico , Ciclooxigenasa 1 , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Humanos , Hiperalgesia/tratamiento farmacológico , Inflamación/tratamiento farmacológico , Masculino , Proteínas de la Membrana , Ratas , Ratas Endogámicas Lew , Ratas Sprague-DawleyRESUMEN
Two compounds (celecoxib and valdecoxib) from the diarylheterocycle class of cyclooxygenase inhibitors were radiolabeled and used to characterize their binding to cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), several single-point variants of COX-2 (Val523Ile, Tyr355Ala, Arg120Ala, Arg120Gln, Arg120Asn) and one triple-point variant of COX-2 [Val523Ile, Arg513His, Val434Ile (IHI)]. We demonstrate highly specific and saturable binding of these inhibitors to COX-2. Under the same assay conditions, little or no specific binding to COX-1 could be detected. The affinity of [(3)H]celecoxib for COX-2 (K(D) = 2.3 nM) was similar to the affinity of [(3)H]valdecoxib (K(D) = 3.2 nM). The binding to COX-2 seems to be both rapid and slowly reversible with association rates of 5.8 x 10(6)/M/min and 4.5 x 10(6)/M/min and dissociation rates of 14 x 10(-3)/min (t(1/2) = 50 min) and 7.0 x 10(-3)/min (t(1/2) = 98 min) for [(3)H]celecoxib and [(3)H]valdecoxib, respectively. These association rates increased (4- to 11-fold) when the charged arginine residue located at the entrance to the main hydrophobic channel was mutated to smaller uncharged amino acids (Arg120Ala, Arg120Gln, and Arg120Asn). Mutation of residues located within the active site of COX-2 that define a 'side pocket' (Tyr355Ala, Val523Ile, IHI) of the main channel had a greater effect on the dissociation rate than the association rate. These mutations, which modified the shape of and access to the 'side pocket', affected the binding affinity of [(3)H]valdecoxib more than that of [(3)H]celecoxib. These binding studies provide direct insight into the properties and binding constants of celecoxib and valdecoxib to COX-2.
Asunto(s)
Isoenzimas/metabolismo , Isoxazoles/farmacología , Prostaglandina-Endoperóxido Sintasas/metabolismo , Sulfonamidas/farmacología , Animales , Sitios de Unión , Celecoxib , Ciclooxigenasa 1 , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa/farmacología , Isoenzimas/efectos de los fármacos , Proteínas de la Membrana , Ratones , Prostaglandina-Endoperóxido Sintasas/efectos de los fármacos , Pirazoles , Proteínas Recombinantes/efectos de los fármacos , Proteínas Recombinantes/metabolismo , Ovinos , TritioRESUMEN
The synthesis and biological evaluation of a series of heterocyclic analogues of the previously reported LTA(4) hydrolase inhibitor 1b are described. Imidazopyridine and purine analogues are specifically highlighted with several demonstrating excellent potency in our in vitro assays, as well as good oral activity in a mouse ex vivo assay.
Asunto(s)
Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacología , Epóxido Hidrolasas/antagonistas & inhibidores , Purinas/síntesis química , Purinas/farmacología , Piridinas/síntesis química , Piridinas/farmacología , Animales , Epóxido Hidrolasas/sangre , Compuestos Heterocíclicos/síntesis química , Compuestos Heterocíclicos/farmacología , Humanos , Técnicas In Vitro , Indicadores y Reactivos , Ratones , Proteínas Recombinantes/antagonistas & inhibidores , Relación Estructura-ActividadRESUMEN
The synthesis and biological evaluation of a series of functionalized pyrrolidine- and piperidine-containing analogues of our lead LTA(4) hydrolase inhibitor, SC-57461A, is described. A number of compounds showed excellent potency in our in vitro screens and several demonstrated good oral activity in a mouse ex vivo assay. These efforts led to the identification of SC-56938 (14) as a potent, orally active inhibitor of LTA(4) hydrolase.
Asunto(s)
Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Epóxido Hidrolasas/antagonistas & inhibidores , Piperidinas/química , Piperidinas/farmacología , Pirrolidinas/química , Pirrolidinas/farmacología , beta-Alanina/análogos & derivados , beta-Alanina/química , Administración Oral , Animales , Humanos , Concentración 50 Inhibidora , Ratones , Relación Estructura-ActividadRESUMEN
Cyclooxygenase (COX) performs the critical initial reaction in the arachidonic metabolic cascade, leading to formation of proinflammatory prostaglandins, thromboxanes, and prostacyclins. The discovery of a second COX isoform (COX-2) associated with inflammation led to agents that selectively inhibit COX-2. Cyclooxygenase-2 inhibitors are also being developed for canine applications. To assess the compound potency on canine enzymes, canine COX-1 and COX-2 were cloned, expressed, and purified. Cyclooxygenase-1 was cloned from a canine kidney complementary DNA (cDNA) library, with 96 % sequence homology to human COX-1. Cyclooxygenase-2 was cloned from canine kidney and lipopolysaccharide-stimulated macrophage cDNA libraries, with a 93 % sequence homology to human COX-2. The arachidonic acid Michaelis constants for canine COX-1 and COX-2 were 4.8 and 6.6 micrometer, respectively, compared with 9.6 and 10.2 micrometer for ovine. Inhibition results indicated that, for all compounds tested, there was no significant difference between potencies determined for canine enzymes and those for human enzymes.
Asunto(s)
Inhibidores de la Ciclooxigenasa/farmacología , Perros/genética , Isoenzimas/antagonistas & inhibidores , Isoenzimas/genética , Prostaglandina-Endoperóxido Sintasas/genética , Secuencia de Aminoácidos , Animales , Antiinflamatorios no Esteroideos/farmacología , Clonación Molecular , Ciclooxigenasa 1 , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Relación Dosis-Respuesta a Droga , Expresión Génica , Biblioteca de Genes , Humanos , Isoenzimas/biosíntesis , Isoenzimas/metabolismo , Riñón/enzimología , Proteínas de la Membrana , Reacción en Cadena de la Polimerasa , Prostaglandina-Endoperóxido Sintasas/biosíntesis , Prostaglandina-Endoperóxido Sintasas/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Alineación de Secuencia , Especificidad por SustratoRESUMEN
Leukotriene B(4) (LTB(4)) is a potent, proinflammatory mediator involved in the pathogenesis of a number of diseases including inflammatory bowel disease, psoriasis, rheumatoid arthritis, and asthma. The enzyme LTA(4) hydrolase represents an attractive target for pharmacological intervention in these disease states, since the action of this enzyme is the rate-limiting step in the production of LTB(4). Our previous efforts focused on the exploration of a series of analogues related to screening hit SC-22716 (1, 1-[2-(4-phenylphenoxy)ethyl]pyrrolidine) and resulted in the identification of potent, orally active inhibitors such as 2. Additional structure-activity relationship studies around this structural class resulted in the identification of a series of alpha-, beta-, and gamma-amino acid analogues that are potent inhibitors of the LTA(4) hydrolase enzyme and demonstrated good oral activity in a mouse ex vivo whole blood LTB(4) production assay. The efforts leading to the identification of clinical candidate SC-57461A (8d, 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid) are described.